Amparo P. F.
- Country
- Spain
- Department
- N/A
Research Overview
- Phase 3 Randomized Double-Blind Study of MT-7117 (Dersimelagon Phosphate) in Erythropoietic Protoporphyria and X-Linked Protoporphyria Patients
- Long-term Safety and Tolerability Evaluation of Oral Dersimelagon (MT-7117) in Erythropoietic Protoporphyria and X-Linked Protoporphyria Patients
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of ESK-001 and Apremilast in Moderate to Severe Plaque Psoriasis Patients
Data & Insights
Has run more than one trial at 16 of 94 partner sites.
Specializations
Dermatological Conditions
This investigator specializes in treating moderate to severe plaque psoriasis, conducting research into innovative therapeutic approaches for managing this chronic skin condition.
- Psoriasis Management
- Long-term Treatment Evaluation
- Novel Therapeutic Assessment
The research focus includes evaluating treatment efficacy and monitoring long-term safety outcomes in psoriasis patients.
Rare Genetic Disorders
The investigator has developed expertise in treating rare photodermatological conditions, specifically Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP).
- Photosensitivity Management
- Genetic Photodermatoses
- Sun Protection Strategies
Research activities center on developing treatments to improve sun tolerance and reduce photosensitivity symptoms in affected individuals.
Therapeutic Innovation
The investigator examines novel oral therapeutic agents for both common and rare dermatological conditions, focusing on long-term safety and efficacy profiles.
- Treatment Durability
- Safety Monitoring
- Clinical Response Assessment
Studies emphasize the evaluation of innovative medications for chronic dermatological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.